钙化性主动脉瓣疾病:从分子细胞机制到药物治疗
钙化性主动脉瓣疾病(CAVD)涵盖从微观改变到纤维钙化性瓣叶重塑,最终导致主动脉瓣狭窄、心力衰竭和过早死亡。他汀类药物虽有效降低低密度脂蛋白胆固醇,却未能影响CAVD进展或改善结局;近期完成的II期试验提示针对其他靶点的药物策略有望无创改变疾病进程。本文阐述CAVD病理生物学关键环节及新兴治疗靶点。
要点
- CAVD与动脉粥样硬化共享高胆固醇血症和高血压等危险因素,但分子细胞机制显著不同。
- 他汀降低低密度脂蛋白胆固醇未能延缓CAVD进展或改善患者结局。
- 近期II期试验提示脂蛋白(a)、MGP、sGC、DPP-4等靶点药物可能改变CAVD病程。
核心结论
- CAVD是涉及内皮屏障受损、脂质归巢、免疫细胞浸润及磷钙代谢紊乱的连续疾病过程,最终导致左心室流出道梗阻。
- 他汀类药物虽有效用于动脉粥样硬化心血管病二级预防,但未能影响CAVD进展或改善患者结局。
- 近期完成的II期试验为针对其他CAVD发病机制靶点的药物治疗带来了改变疾病进程的希望。
研究设计与样本
- 本文为综述,系统阐述CAVD从分子和细胞机制到药物治疗的病理生物学关键环节及新兴靶点。
主要发现
- CAVD从微观改变进展为显著的纤维钙化性瓣叶重塑,最终导致主动脉瓣狭窄、心力衰竭和过早死亡。
- CAVD与动脉粥样硬化共享高胆固醇血症和(收缩期)高血压等传统危险因素,但分子和细胞机制显著不同。
- 他汀诱导的低密度脂蛋白胆固醇降低始终未能影响CAVD进展或改善患者结局。
- CAVD病理涉及内皮屏障功能受损、脂质归巢、免疫细胞浸润及磷钙代谢紊乱,共同维持促炎/促骨生成微环境。
- 瓣膜间质细胞在该微环境中逐渐获得肌纤维母细胞/成骨细胞样特性,促进纤维钙化性瓣叶重塑。
临床怎么用
- 他汀类药物不应以延缓CAVD进展或改善结局为目的用于CAVD患者。
- 脂蛋白(a)、矿物结合基质Gla蛋白、可溶性鸟苷酸环化酶、二肽基肽酶-4及调控磷钙代谢和瓣膜血管紧张素II合成的候选靶点值得关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling, culminating in aortic stenosis, heart failure, and ultimately premature death. Traditional risk factors, such as hypercholesterolaemia and (systolic) hypertension, are shared among atherosclerotic cardiovascular disease and CAVD, yet the molecular and cellular mechanisms differ markedly. Statin-induced low-density lipoprotein cholesterol lowering, a remedy highly effective for secondary prevention of atherosclerotic cardiovascular disease, consistently failed to impact CAVD progression or to improve patient outcomes. However, recently completed phase II trials provide hope that pharmaceutical tactics directed at other targets implicated in CAVD pathogenesis offer an avenue to alter the course of the disease non-invasively. Herein, we delineate key players of CAVD pathobiology, outline mechanisms that entail compromised endothelial barrier function, and promote lipid homing, immune-cell infiltration, and deranged phospho-calcium metabolism that collectively perpetuate a pro-inflammatory/pro-osteogenic milieu in which valvular interstitial cells increasingly adopt myofibro-/osteoblast-like properties, thereby fostering fibro-calcific leaflet remodelling and eventually resulting in left ventricular outflow obstruction. We provide a glimpse into the most promising targets on the horizon, including lipoprotein(a), mineral-binding matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase-4 as well as candidates involved in regulating phospho-calcium metabolism and valvular angiotensin II synthesis and ultimately discuss their potential for a future therapy of this insidious disease.
引用
- Kraler S, Blaser MC, Aikawa E, et al. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J. 2022. PMID: 34849696. doi:10.1093/eurheartj/ehab757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。